Renalytix has moved sharply higher, withLSE:RENX gaining 12.99% on 24 August 2026.
The 4.55% rise in Abingdon Health shares was likely supported by the company’s recent trading update, which indicated strong revenue growth and progress toward sustainable profitability. Growth accelerated during the latter part of the period, with contract development work emerging as an important contributor.
CRISM Therapeutics Corporation (LSE:CRTX) is a UK clinical-stage drug-delivery company developing implantable products for the localised and sustained delivery of chemotherapy. Its proprietary ChemoSeed technology is intended to deliver therapeutic concentrations directly into solid tumours or the tissue surrounding a surgically removed tumour.
Hemogenyx Pharmaceuticals Plc is a clinical-stage biopharmaceutical company developing treatments for blood cancers, bone-marrow disorders and severe immune-related diseases. Its lead candidate, HG-CT-1, is a personalised CAR-T cell therapy designed to target a protein commonly expressed on malignant cells in acute myeloid leukaemia and …
Allergy Therapeutics plc is an international commercial biotechnology company focused on the diagnosis and treatment of allergic disorders. Its portfolio includes injectable immunotherapies for pollen, venom and other allergies, alongside a clinical pipeline targeting food allergies. The company sells proprietary and third-party products through …
EDX Medical Group PLC develops and supplies advanced diagnostic products and digitally enabled healthcare services designed to improve disease detection and support personalised treatment. The recent share-price strength appears to reflect a combination of fresh growth capital, progress with prospective employer contracts and confidence …
MedPal AI LSE:MPAL was in focus on 21 August 2026 after the shares declined2.50% to approximately 3.90p.
NAHL Group Plc became a notable mover among UK-listed small-cap stocks on 21 August 2026 after its shares fell4.02%. The decline has drawn attention because the company had recently delivered an encouraging first-half trading update, with revenue, underlying operating profit and free cash flow …
Allergy Therapeutics LSE:AGY was in focus on 21 August 2026 after the shares declined2.86%, closing at approximately5.10p, compared with 5.25p previously. The stock opened around 5.25p and traded in a relatively wide range during the session, illustrating the limited liquidity that can affect the …
Bioventix LSE:BVXP was firmly in focus on 21 August 2026 after the shares declined2.78%, ending the session around1,750p.